A PHASE 1, RANDOMIZED, PLACEBO-CONTROLLED STUDY WITH A DOUBLE-BLIND PERIOD
WITH OPEN-LABEL EXTENSION PERIOD TO EVALUATE THE SAFETY, TOLERABILITY,
PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRATHECALLY ADMINISTERED ALN-
5288 IN ADULT PATIENTS WITH ALZHEIMER¿S DISEASE
- Registry ID
- ALN-5288-001
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- ALNYLAM PHARMACEUTICALS INC
- Start date
- 2025-10-10
- Last update
- 2025-09-10
Conditions
Related clinical trials
- A PHASE 1/2A PLACEBO-CONTROLLED DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ARO-MAPT-SC IN HEALTHY SUBJECTS AND SUBJECTS WITH EARLY ALZHEIMER’S DISEASE.
- PHASE 2/3, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF EXV-802 AND EXV- 801 IN THE TREATMENT OF AGITATION IN PARTICIPANTS WITH ALZHEIMER’S DISEASE DEMENTIA
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,
PARALLEL GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF
KARXT + KARX-EC FOR THE TREATMENT OF AGITATION ASSOCIATED
WITH ALZHEIMER’S DISEASE (ADAGIO-1)
- A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY
STUDY OF TRONTINEMAB IN PARTICIPANTS WITH EARLY
SYMPTOMATIC ALZHEIMER’S DISEASE (MCI TO MILD DEMENTIA DUE
TO AD)
- A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,
PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY
STUDY OF TRONTINEMAB IN PARTICIPANTS WITH EARLY
SYMPTOMATIC ALZHEIMER’S DISEASE (MCI TO MILD DEMENTIA DUE
TO AD)
- A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, SINGLE ASCENDING DOSE
STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY,
PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7812653
FOLLOWING INTRATHECAL ADMINISTRATION IN PARTICIPANTS
WITH EARLY SYMPTOMATIC ALZHEIMER’S DISEASE
View on source registry